EUDA Health Partners on iPSC Cell Therapy for Oncology and Wellness — EUDA Health Holdings Limited

Event summary

EUDA Health signed a non-binding MOU with GO POSB and SIIT on July 15, 2026 to develop off-the-shelf iPSC cell therapies for oncology and wellness applications.
GO POSB will provide its proprietary iPSC platform and clinical-grade universal tumor organoid bank.
SIIT will contribute NK and NK-TCR cell engineering capabilities along with GMP manufacturing expertise.
EUDA Health will fund the collaboration, facilitate commercialization, and support global market access.

The big picture

This collaboration positions EUDA Health at the forefront of the growing regenerative medicine sector, targeting both oncology and wellness applications. The integration of GO POSB’s iPSC platform with SIIT’s NK cell engineering capabilities aims to create off-the-shelf therapies that could disrupt traditional treatment paradigms. Success hinges on navigating regulatory hurdles and securing adequate funding for clinical evaluations.

What we're watching

Regulatory Approvals: The pace at which the collaboration secures regulatory approvals in key markets will determine the timeline for commercialization.
Funding Requirements: Whether EUDA Health can secure sufficient funding to support the development and manufacturing of these investigational therapies.
Market Penetration: How effectively EUDA Health can leverage its distribution network in Asia to commercialize these next-generation cell therapies globally.